×
Hero Background

Plasma Fractionation Companies

ID: MRFR/HC/5928-CR
200 Pages
Rahul Gotadki
July 2025

Plasma fractionation companies are instrumental in the production of therapeutic plasma-derived products. Through sophisticated processes, they fractionate plasma into its individual components, isolating valuable proteins such as immunoglobulins, clotting factors, and albumin. These companies provide critical supplies for treating a variety of medical conditions, including immune deficiencies, hemophilia, and neurological disorders. Their commitment to quality and safety ensures the availability of life-saving therapies derived from plasma.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Plasma Fractionation Market Research Report – Global Forecast till 2035 Infographic
Summary Table of Contents Segmentation Download PDF

Top Industry Leaders in the Plasma Fractionation Market

Plasma Fractionation Key Companies

 


Latest Plasma Fractionation Companies Update


CSL Behring (Australia)Received FDA approval for the 50mL/10gm prefilled syringe for Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) for patients with PI and CIPD.Partnered with research institutions to develop novel plasma-derived therapies for unmet medical needs.


Grifols (Spain)Launched their XEMBIFY, a 20% subcutaneous immunoglobulin (SCIG) approved for various primary immunodeficiency diseases in Europe.Focused on expanding their footprint in the growing SCIG market with convenient and patient-preferred delivery options.


Takeda Pharmaceutical (Japan) Collaborated with BPL (UK) to establish a joint venture plasma fractionation facility in India, expanding their global plasma collection and manufacturing capabilities.Focused on developing next-generation plasma-derived medicines with enhanced efficacy and targeted therapeutic applications.


Baxter International Received CE Mark approval for their VIGEVWO™ (immunoglobulin, human-normal, liquid), offering broad-spectrum antibody protection for immune-compromised individuals.Partnered with healthcare providers to improve access to plasma-derived therapies for patients in underserved regions.


Octapharma Signed a strategic partnership with Kedrion (Italy) for collaborative research and development of new plasma-derived medicines, further advancing the field.Emphasized their commitment to sustainable plasma collection practices and environmental responsibility.


List of Plasma Fractionation companies in the market

  • CSL Behring (US)

  • Grifols Therapeutics (Spain)

  • Baxter International Inc (US)

  • Mitsubishi Tanabe (Japan)

  • Takeda Pharmaceutical (Japan)

  • Octapharma AG (Switzerland)

  • Hualan Bio (China)

  • Kedrion S.p.A (Italy)

  • LFB group (France)

  • Biotest AG (Germany)